Association of Preoperative Plasma D-Dimer and Fibrinogen and Osteosarcoma Outcome

Yanchuan Pu1*, Jin Wang1, Jianshu Wang2 and Shizhong Wang1*

1 Department of Orthopedics, Wuwei City People’s Hospital, Wuwei, China, 2 Department of Bone Oncology, Gansu Cancer Hospital, Lanzhou, China

Objective: We aimed to evaluate the utility of preoperative D-dimer and plasma fibrinogen (PF) levels as useful markers for predicting the clinical value of patients with osteosarcoma.

Methods: 145 enrolled patients with osteosarcoma were studied retrospectively. We determined the critical values of D-dimer and PF by receiver operating characteristic curve analysis. Cox regression analysis was used to assess prognostic role of the D-dimer and PF levels among osteosarcoma patients.

Results: The critical values of D-dimer and PF were calculated to be 0.46 µg/mL and 3.34 mg/mL, respectively. Upregulation of D-dimer and PF showed positive correlations with a higher clinical stage, tumour metastasis and recurrence. Survival curve results confirmed that osteosarcoma patients with higher levels of D-dimer and PF predicted worse overall survival (OS) and progression-free survival (PFS). Moreover, only a high D-dimer level was associated with a shorter OS (P = 0.013) and PFS (P = 0.042) in both the univariate and multivariate analysis.

Conclusion: Elevated preoperative D-dimer levels are correlated with aggressive clinicopathological features and poor survival outcomes, which indicates that assessment of the D-dimer could be a useful prognostic marker in osteosarcoma.

Keywords: progression-free survival, osteosarcoma, prognosis, overall survival, d-dimer, plasma fibrinogen

INTRODUCTION

Osteosarcoma is the most common primary bone tumour in young patients. The peak incidence of osteosarcoma occurs in patients who are 18 years old (1). Though comprehensive treatments (neoadjuvant chemotherapy, surgery and adjuvant chemotherapy) have been developed, the 5-year overall survival (OS) rate of patients with osteosarcoma without metastasis is less than 70%, while that of patients with metastatic disease is less than 20% (2). Thus, new prognostic markers to identify metastatic disease in osteosarcoma are essential and could be helpful for conducting a systematic assessment of the prognosis of osteosarcoma and providing accurate guidance for individualized clinical treatment.

To date, several investigators have confirmed an association between the activation of the coagulation/fibrinolysis system and tumour progression (3, 4). Based on the available literature, the two parts (plasma fibrinogen (PF) and D-dimer) of the plasminogen-plasmin and coagulation system may be related to
prognosis in osteosarcoma. Fibrinogen, a molecule synthesized by liver parenchyma cells in response to cytokine stimulation, participates in both the inflammatory response and carcinoma progression (5). Several studies have suggested that PF levels are upregulated in several carcinomas and might be associated with tumour progression and metastasis (6–8). However, no study has reported the relationship between PF and osteosarcoma prognosis.

Plasma D-dimer is a signal of hyperfibrinolysis and an end-product of fibrin degradation that can be detected in blood samples (9). An elevated D-dimer level before surgery has been shown to be closely related to the occurrence and development of a variety of malignancies, such as gastric cancer (10), ovarian cancer (11), and gynaecological carcinomas (12). Huang et al. (13) demonstrated that D-dimer is a biomarker for chemotherapy response in patients with osteosarcoma. In addition, other data also confirmed that D-dimer was a predictor of patients with metastatic osteosarcoma treated with second-line chemotherapy (14). However, its effectiveness in prognosis prediction of osteosarcoma has not been fully characterized.

Hence, we examined the D-dimer and PF levels in nonmetastatic and metastatic primary osteosarcoma samples to elucidate the relationship between these markers and the associated clinical features.

MATERIALS AND METHODS

Patient Selection

Between July 2006 and December 2015, 160 consecutive pathologically confirmed osteosarcoma patients who were treated at Wuwei People’s Hospital (Wuwei, China) were enrolled. Patients were followed until January 30, 2021. The mean follow-up was 86 months (range 3–123). Only pathological samples taken before chemoradiotherapy were collected, and none of the patients received chemoradiotherapy before the surgery.

The inclusion criteria were as follows: (1) osteosarcoma confirmed by pathology; (2) patients undergoing surgery in our hospital from July 2006 to December 2015; and (3) sufficient clinical data in the medical records. Patients who received second-line chemotherapy. Two different pathologists assessed the histopathology of each sample to confirm the diagnosis of osteosarcoma according to the World Health Organization’s classification of bone tumours. Ultimately, 145 patients diagnosed with osteosarcoma were included, including 104 men and 41 women. The Ethics Committees of Wuwei City People’s Hospital approved the research.

Clinical features, including sex, age, tumour size, clinical stage, pathological fracture, metastasis and recurrence status, physical examination and smoking status, were noted. The levels of D-dimer and PF were detected in all patients within 7 days before the first treatment. PF and D-dimer levels were tested using an automatic coagulation analyser (Stago, France). PF and D-dimer levels were measured by the clotting method and immunoturbidimetry assays, respectively.

Optimal Prognostic Cut-Off Values for D-Dimer and PF

The mean D-dimer and PF levels were 0.56 µg/mL (SD, ± 0.18) and 3.44 g/L (SD, ± 1.96), respectively. According to the findings of the receiver operating characteristic curve (ROC) analysis, the optimum cut-off values were 0.46 µg/mL for preoperative D-dimer (Figure 1A) and 3.34 mg/mL for preoperative PF (Figure 1B). The maximum area under the curve (AUC) values for the ROC were 0.720 and 0.697, respectively.

**FIGURE 1** | ROC curve analysis for determination of optimal cut-off values of D-dimer (A) and PF (B) levels in 5-year OS.
curves corresponding to D-dimer and PF were 0.720 (95% CI 0.639 to 0.791) and 0.697 (95% CI 0.615 to 0.771), respectively. The sensitivities of D-dimer and PF were 0.854 and 0.855, respectively, while the specificities were 0.626 and 0.627, respectively. According to the optimal cut-off values for D-dimer and PF, the patients were divided into the following groups: high PF group (> 3.34 mg/mL; n = 84) and low PF group (≤ 3.34 mg/mL; n = 61) and high D-dimer group (> 0.46 µg/mL; n = 95) and low D-dimer group (≤ 0.46 µg/mL; n = 50).

**Statistical Methods**

SPSS 26.0 (IBM, Armonk, NY, USA) and GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA) software were used for statistical analysis. ROC curves for 5-year OS prediction were established to assess the optimal cut-off values of coagulation parameters so the parameters could be treated as binary variables. A chi-square test was performed to analyse the relationships between clinicopathological factors and coagulation indexes. Survival was assessed by creating a Kaplan-Meier curve; paired comparisons were made using a log-rank test. The univariate and multivariate analyses was used to estimate the correlation between D-dimer and PF and survival outcome (OS and progression-free survival (PFS). P < 0.05 was considered to indicate statistical significance.

**RESULTS**

**Clinicopathological Features**

Between July 2006 and December 2015, 160 patients with osteosarcoma were first diagnosed in our hospital. After employing the strict inclusion and exclusion criteria, 145 osteosarcoma patients were included. The study cohort consisted of 104 (71.7%) men and 41 (28.3%) women among the 145 patients, with a median age of 18 years (8-53 years). There were 69 patients (47.6%) with tumour stage (I-II) and 76 patients (52.4%) with tumour stage (III-IV). The tumour diameter was 8 cm or less for 70 patients (48.3%) and more than 8 cm for 75 patients (51.7%). In addition, 73 patients (50.3%) experienced metastases, including pulmonary metastases (46) and bone metastases (27), while the other 72 patients did not experience metastasis (49.7%). Seventy-six patients (52.4%) experienced tumour recurrence, including 61 who experienced it once, 12 who experienced it twice, and 2 patients who experienced it three times, while the other 69 patients did not experience tumour recurrence (47.6%). Twenty-seven patients (18.6%) experienced pathological fracture during the follow-up.

**Associations of D-Dimer and PF Levels With Clinicopathological Features**

As shown in Table 1, the baseline characteristics of osteosarcoma patients based on the D-dimer and PF groups are shown. Our results indicated that metastasis and recurrence at diagnosis were significantly correlated with a high D-dimer level (P = 0.012 and P = 0.030) and a high PF level (P < 0.001 and P = 0.019). Advanced tumour stage was closely associated with high D-dimer and PF levels (P = 0.012 and P = 0.044). The distribution of sex, age, tumour size, pathological fracture, and operation mode did not differ significantly between the D-dimer and PF groups.

| Characteristic | Total (%) | PF | D-dimer |
|---------------|-----------|----|---------|
|               | >3.34 g/L | ≤3.34 g/L | >0.46 µg/mL | ≤0.46 µg/mL |
| Gender        |           |    |         |           |      |
| Male          | 104 (71.7)| 58 | 46      | 70         | 34   |
| Female        | 41 (28.3)| 26 | 15      | 25         | 16   |
| Age, years    |           |    |         |           |      |
| <18           | 64 (44.1)| 37 | 27      | 42         | 22   |
| ≥18           | 81 (55.9)| 47 | 34      | 53         | 28   |
| Tumour size, cm |       |    |         |           |      |
| <8            | 75 (51.7)| 40 | 36      | 47         | 28   |
| ≥8            | 70 (48.3)| 44 | 26      | 48         | 22   |
| Pathological fracture |   |    |         |           |      |
| No            | 118 (81.4)| 68 | 50      | 77         | 41   |
| Yes           | 27 (18.6)| 18 | 13      | 18         | 9    |
| Operation     |           |    |         |           |      |
| Amputation    | 18 (12.4)| 11 | 7       | 10         | 8    |
| Salvage       | 127 (87.6)| 73 | 54      | 85         | 42   |
| Clinical stage |        |    |         |           |      |
| I/II          | 69 (47.6)| 34 | 35      | 38         | 31   |
| III/IV        | 76 (52.4)| 50 | 26      | 57         | 19   |
| Metastasis    |           |    |         |           |      |
| Absent        | 72 (49.7)| 30 | 42      | <0.001     | 40   |
| Present       | 73 (50.3)| 54 | 19      | 55         | 18   |
| Recurrence    |           |    |         |           |      |
| Absent        | 69 (47.6)| 33 | 36      | 39         | 30   |
| Present       | 76 (52.4)| 51 | 25      | 56         | 20   |
Prognostic Factors for OS in Patients With Osteosarcoma

The potential prognostic value of D-dimer (P < 0.001) and PF (P = 0.013) levels for predicting OS was evaluated by Kaplan-Meier survival analysis (Figures 2A, B). The D-dimer-high and D-dimer-low groups showed 5-year OS rates of 52.4% and 76.6%, respectively. The PF-high and PF-low groups showed 5-year OS rates of 53.7 and 77.1%, respectively.

The univariate analysis identified tumour clinical stage, metastasis, recurrence, PF level and D-dimer level (all P < 0.001). In addition, the multivariate Cox proportional hazard model suggested that several factors [metastasis (P < 0.001), recurrence (P = 0.006), and D-dimer level (P = 0.013)] were associated with the OS of patients (Table 2).

Prognostic Factors for PFS in Patients With Osteosarcoma

The survival curve indicated that osteosarcoma patients with higher D-dimer (P = 0.001) and PF (P = 0.015) levels had poorer PFS (Figures 2C, D).

The univariate analysis indicated that D-dimer (P = 0.002) and PF (P = 0.017) level were significantly related to PFS, as were clinical stage, metastasis, and recurrence (all P < 0.05). Furthermore, the multivariate analysis confirmed that elevated D-dimer levels (P = 0.042), metastasis (P = 0.001), and recurrence (P = 0.001) remained independent factors of PFS in osteosarcoma patients (Table 3).

DISCUSSION

Osteosarcoma is a highly complex and heterogeneous neoplasm with different recurrence and progression rates. Understanding its molecular pathogenesis and identifying specific biomarkers are necessary for improving the prognosis of osteosarcoma. It has been widely recognized that there is a link between tumours and haemostasis (15). The plasma D-dimer and PF levels have been widely considered reliable biomarkers of haemostasis and fibrinolysis activation. Previous research confirmed that high levels of these two coagulation parameters (D-dimer and PF) are risk factors predicting worse survival outcomes in various solid tumours. However, few studies have focused on the effect of the two coagulation parameters in patients with osteosarcoma. Therefore, we evaluated the prognostic significance of these two coagulation parameters in a cohort of osteosarcoma patients.

![FIGURE 2](#)| Kaplan-Meier curves for OS (A, B) and PFS (C, D) for osteosarcoma patients stratified by preoperative D-dimer and PF.
In the present research, our results showed the following: (a) upregulation of D-dimer and PF predicted a shorter survival time for osteosarcoma patients; (b) D-dimer and PF levels were closely related to a more advanced tumour stage, metastasis and recurrence in osteosarcoma patients; (c) aberrant D-dimer and PF levels were not strongly related to sex, age, tumour size, pathological fracture, or operation mode in osteosarcoma patients; and (d) only the D-dimer can be an independent prognostic parameter in osteosarcoma. This result may be because osteosarcoma patients are more likely to have high levels of D-dimer and PF. Although further validation and research are needed, our findings provide new insights into the prognostic significance of D-dimer and PF levels in osteosarcoma patients.

The biological mechanism of D-dimer explains its prognostic significance in osteosarcoma. In osteosarcoma, cancer cells can alter the balance among the coagulation, anticoagulation, and fibrinolytic systems by various mechanism, resulting in hyperactivity of coagulation and fibrinolysis system via a number of mechanisms, resulting in hyperactivity in the

| Characteristic | Univariate | Multivariate |
|---------------|------------|--------------|
|               | Hazard Ratio | 95% CI | P value | Hazard Ratio | 95% CI | P value |
| Age, years | ≥ 18 vs < 18 | 1.189 | 0.740-1.909 | 0.474 | 1.381 | 0.849-2.246 | 0.194 |
| Gender | Male vs Female | 0.875 | 0.512-1.494 | 0.625 | 0.253 | 0.058-1.104 | 0.068 |
| Tumour size, cm | ≥ 8 vs < 8 | 1.504 | 0.937-2.412 | 0.091 | 0.898 | 0.513-1.571 | 0.706 |
| Pathological fracture | Present vs Absent | 1.264 | 0.703-2.273 | 0.434 | 0.886 | 0.471-1.668 | 0.709 |
| Operation | Amputation vs Salvage | 1.160 | 0.679-1.981 | 0.586 | 4.218 | 0.964-18.462 | 0.056 |
| Clinical stage | III/IV vs < III/IV | 2.428 | 1.482-3.977 | <0.001 | 1.371 | 0.440-4.270 | 0.587 |
| Metastasis | Present vs Absent | 3.119 | 1.843-5.276 | <0.001 | 2.661 | 1.551-4.563 | <0.001 |
| Recurrence | Present vs Absent | 2.324 | 1.425-3.788 | 0.001 | 2.002 | 1.219-3.287 | 0.006 |
| PF | High vs Low | 1.833 | 1.124-2.988 | 0.015 | 1.069 | 0.625-1.826 | 0.808 |
| D-dimer | High vs Low | 2.782 | 1.571-4.928 | <0.001 | 2.117 | 1.174-3.818 | 0.013 |

| Characteristic | Univariate | Multivariate |
|---------------|------------|--------------|
|               | Hazard Ratio | 95% CI | P value | Hazard Ratio | 95% CI | P value |
| Age, years | ≥ 18 vs < 18 | 1.187 | 0.759-1.906 | 0.478 | 1.343 | 0.825-2.185 | 0.236 |
| Gender | Male vs Female | 0.863 | 0.505-1.476 | 0.591 | 0.295 | 0.082-1.062 | 0.062 |
| Tumour size, cm | ≥ 8 vs < 8 | 1.437 | 0.897-2.301 | 0.132 | 0.942 | 0.541-1.637 | 0.831 |
| Pathological fracture | Present vs Absent | 1.375 | 0.763-2.480 | 0.289 | 1.002 | 0.526-1.907 | 0.996 |
| Operation | Amputation vs Salvage | 1.177 | 0.689-2.011 | 0.743 | 3.534 | 0.980-12.748 | 0.054 |
| Clinical stage | III/IV vs < III/IV | 2.659 | 1.617-4.374 | <0.001 | 1.342 | 0.422-4.267 | 0.619 |
| Metastasis | Present vs Absent | 2.806 | 1.679-4.690 | <0.001 | 2.404 | 1.419-4.074 | 0.001 |
| Recurrence | Present vs Absent | 2.587 | 1.581-4.234 | 0.001 | 2.324 | 1.406-3.841 | 0.001 |
| PF | High vs Low | 1.814 | 1.110-2.964 | 0.017 | 1.145 | 0.667-1.965 | 0.624 |
| D-dimer | High vs Low | 2.511 | 1.418-4.444 | 0.002 | 1.848 | 1.022-3.343 | 0.042 |
coagulation and fibrinolysis systems (16). Plasma D-dimer is a well-known stable degradation product of fibrin that increases during fibrin formation and enhanced fibrinolysis (17). Moreover, the associations between plasma D-dimer and circulating tumour cells (CTCs) observed in relevant studies suggests that the activation of the coagulation cascade could play a crucial role in promoting early tumour metastasis (18).

As an acute-phase glycoprotein, PF is usually related to the maintenance of haemostasis and plays a vital role in tumour cell viability, migration, and invasion (19). For instance, cell line studies have shown that a high concentration of fibrinogen can induce epithelial-mesenchymal transition (EMT) by raising the expression of vimentin and decreasing the expression of E-cadherin, thus enhancing the invasion and migration of cancer cells (20). In addition, fibrinogen can bind to fibroblast growth factors and promote the binding of these growth factors with their receptors on the surface of cancer cells, further enhancing cancer growth and metastasis (21, 22).

Our study is the first to explore the relationships of the levels of D-dimer and PF with the clinicopathological characteristics and survival outcome in osteosarcoma. The concentrations of D-dimer and PF before surgery may also be useful markers for predicting metastasis in osteosarcoma patients following resection. D-dimer and PF can be easily detected in clinical laboratories, and they are effective, simple and inexpensive biomarkers for osteosarcoma.

Our study has limitations. First, the study was retrospective, and it may provide significantly less evidence than a randomized controlled trial. Second, the antibodies used to detect D-dimer and fibrinogen levels were not identical, resulting in different optimal cut-off values. Third, the clinical factors, including ethnicity and age, in this study may also lead to bias.

Overall, this study demonstrated that preoperative elevated D-dimer and PF levels were associated with prognostic factors, including high clinical stage, metastasis and recurrence, that lead to poor OS and PFS rates in osteosarcoma. However, there was no significant correlation between the PF level and the prognosis of osteosarcoma. This study confirmed that the D-dimer level has an adverse effect on the clinicopathological features and metastasis of osteosarcoma. Thus, the D-dimer level can be used as an independent prognostic factor for OS and PFS in osteosarcoma patients. The D-dimer level may be a new candidate for osteosarcoma genotyping and a prognostic indicator of osteosarcoma patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Ethics Committees of Wuwei City People’s Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

All authors design the study, critical revision of the manuscript, and interpretation of data. YP and data acquisition and management and statistical analysis. YP, JW, and JSW drafting of the manuscript. SW study supervision. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.699295/full#supplementary-material

REFERENCES

1. Czarnecka AM, Synoradzki K, Fieley W, Bartnik E, Sobczuk P, Fiedorowicz M, et al. Molecular Biology of Osteosarcoma. Cancers (Basel) (2020) 12:2130. doi: 10.3390/cancers12082130
2. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational Biology of Osteosarcoma. Nat Rev Cancer (2014) 14:722–35. doi: 10.1038/nrc3838
3. Wojtukiewicz MZ, Mysliwiec M, Matuszewski E, Sulkowski S, Zimnoch L, Politynska B, et al. Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. Biomolecules (2021) 11:663. doi: 10.3390/biom11050663
4. Alberti A, Mancin M, Cortinovis D, Bidoli P, Sala L. Disseminated Intravascular Coagulation in Advanced Lung Adenocarcinoma During First-Line Pembrolizumab. Immunotherapy (2020) 12:829–33. doi: 10.2217/ intm-2020-0018
5. Pieters M, Wolberg AS. Fibrinogen and Fibrin: An Illustrated Review. Res Pract Thromb Haemost (2019) 3:161–72. doi: 10.1002/rth2.12191
6. He SS, Wang Y, Yang L, Chen HY, Liang SB, Lu LX, et al. Plasma Fibrinogen Correlates With Metastasis and Is Associated With Prognosis in Human Nasopharyngeal Carcinoma. J Cancer (2017) 8:403–9. doi: 10.7150/jca.17028
7. Wakatsuki K, Matsumoto S, Migitsa K, Ito M, Kunishige T, Nakade H, et al. Preoperative Plasma Fibrinogen Is Associated With Lymph Node Metastasis and Predicts Prognosis in Resectable Esophageal Cancer. World J Surg (2017) 41:2068–77. doi: 10.1007/s00268-017-3991-x
8. Perisanidis C, Psyri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, et al. Prognostic Role of Pretreatment Plasma Fibrinogen in Patients With Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Treat Rev (2015) 41:960–70. doi: 10.1016/j.ctrv.2015.10.002
9. Johnson ED, Schell JC, Rodgers GM. The D-Dimer Assay. Am J Hematol (2019) 94:833–9. doi: 10.1002/ajh.25482
10. Hara K, Aoyama T, Hayashi T, Nakazono M, Nagasawa S, Shimoda Y, et al. Postoperative D-Dimer Elevation Affects Tumor Recurrence and the Long-Term Survival in Gastric Cancer Patients Who Undergo Gastrectomy. Int J Clin Oncol (2020) 25:584–94. doi: 10.1007/s10147-019-01603-x
11. Yamada Y, Kawaguchi R, Iwai K, Niño E, Moriooka S, Tanase Y, et al. Preoperative Plasma D-Dimer Level Is a Useful Prognostic Marker in Ovarian Cancer. J Obstet Gynaecol (2020) 40:102–6. doi: 10.1080/01443615.2019.1606176
12. Komatsu H, Shimada M, Osaku D, Deura I, Sato S, Oishi T, et al. Deep Vein Thrombosis and Serum D-Dimer After Pelvic Lymphadenectomy in
Gynecological Cancer. *Int J Gynecol Cancer* (2020) 30:860–4. doi: 10.1136/ijgc-2019-000914

13. Huang Y, Liu B, Sun Y, Zhang J, Yao Y, He A. The Prognostic Value of D-Dimer Levels in Metastatic Osteosarcoma Patients Treated With Second-Line Chemotherapy. *Oncotarget* (2016) 7:65568–76. doi: 10.18632/oncotarget.11571

14. Huang Y, Shen Z, Yao Y, He A, Min D. The Plasma Concentration of D-Dimer is Associated With Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. *Onco Targets Ther* (2021) 14:213–20. doi: 10.2147/OTT.S278139

15. Soff G. Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview. *Cancer Treat Res* (2019) 179:1–9. doi: 10.1007/978-3-030-20315-3_1

16. Ichikawa J, Cole HA, Magnussen RA, Mignemi NA, Butler M, Holt GE, et al. Thrombin Induces Osteosarcoma Growth, a Function Inhibited by Low Molecular Weight Heparin In Vitro and In Vivo: Procoagulant Nature of Osteosarcoma. *Cancer* (2012) 118:2494–506. doi: 10.1002/cncr.26518

17. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-Dimer Levels Are Associated With Poor Prognosis in Cancer Patients. *Haematologica* (2012) 97:1158–64. doi: 10.3324/haematol.2011.054718

18. Mego M, Karaba M, Minarik G, Benca J, Sedlackova T, Tothova L, et al. Relationship Between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients. *Breast J* (2015) 21:135–60. doi: 10.1111/tbj.12388

19. Zhang F, Wang Y, Sun P, Wang ZQ, Wang DS, Zhang DS, et al. Fibrinogen Promotes Malignant Biological Tumor Behavior Involving Epithelial-Mesenchymal Transition via the P-AKT/p-mTOR Pathway in Esophageal Squamous Cell Carcinoma. *J Cancer Res Clin Oncol* (2017) 143:2413–24. doi: 10.1007/s00432-017-2493-4

20. Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, et al. Clinical and Prognostic Significance of Preoperative Plasma Hyperfibrinogenemia in Gallbladder Cancer Patients Following Surgical Resection: A Retrospective and In Vitro Study. *RMC Cancer* (2014) 14:566. doi: 10.1186/1471-2407-14-566

21. Sahni A, Khornana AA, Baggs RB, Peng H, Francis CW. FGF-2 Binding to Fibrin(ogen) Is Required for Augmented Angiogenesis. *Blood* (2006) 107:126–31. doi: 10.1182/blood-2005-06-2460

22. Wang M, Zhang G, Zhang Y, Cui X, Wang S, Gao S, et al. Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis Through Integrin-AKT Signaling Pathway in Lung Cancer. *Mol Cancer Res* (2020) 18:943–54. doi: 10.1158/1541-7786.MCR-19-1033

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pu, Wang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.